Condition
Cardiac Hypertrophy
Total Trials
5
Recruiting
2
Active
2
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
4Total
P 1 (3)
P 4 (1)
Trial Status
Completed2
Recruiting2
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05302271Phase 1Recruiting
Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia
NCT06424860Phase 1Recruiting
Fish Oil, Metformin and Heart Health in PCOS
NCT01889992Phase 1TerminatedPrimary
Cardiac Allograft Remodeling and Effects of Sirolimus
NCT02545790Completed
Cardiac Remodeling and Circulating Biomarkers in Pediatric Left Ventricular Pressure Loading Lesions
NCT03089333Phase 4Completed
Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects
Showing all 5 trials